EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development

Katherine A Rauen iD, William E Tidyman

Disease Models & Mechanisms · 2024

DOI: 10.1242/dmm.050609 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Disease Models & Mechanisms, 2024. Verfasst von Katherine A Rauen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Genomic Medicine, University of California Davis, Sacramento, CA, 95817, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, ras Proteins, Muscle Development. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RASopathies are rare developmental genetic syndromes caused by germline pathogenic variants in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) signal transduction pathway. Although the incidence of each RASopathy syndrome is rare, collectively, they represent one of the largest groups of multiple congenital anomaly syndromes and have severe developmental consequences. Here, we review our understanding of how RAS/MAPK dysregulation in RASopathies impacts skeletal muscle development and the importance of RAS/MAPK pathway regulation for embryonic myogenesis. We also discuss the complex interactions of this pathway with other intracellular signaling pathways in the regulation of skeletal muscle development and growth, and the opportunities that RASopathy animal models provide for exploring the use of pathway inhibitors, typically used for cancer treatment, to correct the unique skeletal myopathy caused by the dysregulation of this pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, Skeletalras ProteinsMuscle DevelopmentHumansAnimalsSignal TransductionMAP Kinase Signaling SystemMitogen-Activated Protein KinasesDisease Models, Animal

Stichwörter der Autor:innen

Cardio-facio-cutaneous syndromeCostello syndromeMyopathyNeurofibromatosis type 1RAS pathwayRASopathyRare disorderSkeletal myogenesisTreatment

Substanzen

ras ProteinsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Genomic Medicine, University of California Davis, Sacramento, CA, 95817, USA.
  • University of California Davis MIND Institute, Sacramento, CA 95817, USA.

ORCID-Profile: Katherine A Rauen

Förderung

  • NICHD NIH HHS
  • NIAMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Rauen, K. A., & Tidyman, W. E. (2024). RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.050609

Vancouver

Rauen KA, Tidyman WE. RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development. Disease Models & Mechanisms. 2024. doi:10.1242/dmm.050609

BibTeX
@article{Rauen2024,
  author = {Rauen, Katherine A and Tidyman, William E},
  title = {RASopathies – what they reveal about RAS/MAPK signaling in skeletal muscle development},
  journal = {Disease Models & Mechanisms},
  year = {2024},
  doi = {10.1242/dmm.050609}
}
Kostenlos starten →